Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P25208
UPID:
NFYB_HUMAN
Alternative names:
CAAT box DNA-binding protein subunit B; Nuclear transcription factor Y subunit B
Alternative UPACC:
P25208; A8K7B9; Q96IY8
Background:
Nuclear transcription factor Y subunit beta, also known as CAAT box DNA-binding protein subunit B, plays a pivotal role in gene expression. It is a component of the NF-Y heterotrimeric transcription factor, which specifically binds to a 5'-CCAAT-3' box motif in the promoters of target genes. NF-Y is unique in its ability to act as both an activator and a repressor, modulating gene expression in response to cellular context and interacting cofactors.
Therapeutic significance:
Understanding the role of Nuclear transcription factor Y subunit beta could open doors to potential therapeutic strategies. Its central role in regulating gene expression makes it a key target for modulating disease-related genes, offering a pathway to novel treatments.